Weekly Ophthalmic Newsletter

1. Bausch + Lomb Acquires ELIOS System

Bausch + Lomb has officially acquired the ELIOS System, a groundbreaking minimally invasive surgical tool for glaucoma treatment.

The ELIOS System utilizes excimer laser technology to create precise micro-incisions, effectively reducing intraocular pressure (IOP) in glaucoma patients. This acquisition positions Bausch + Lomb as a leader in delivering innovative glaucoma solutions, complementing their robust surgical portfolio.

This move emphasizes the importance of expanding minimally invasive glaucoma surgery (MIGS) options to meet the growing demand for safer, more effective treatments.

?? Learn how this acquisition could transform glaucoma care

2. Empagliflozin Linked to Reduced Progression of Diabetic Retinopathy

A new study has linked the diabetes drug Empagliflozin, an SGLT2 inhibitor, to a lower risk of diabetic retinopathy progression.

Researchers found that patients taking Empagliflozin experienced slower disease progression and improved glycemic control, offering potential new hope for diabetic patients facing vision loss.

These findings underscore the broader benefits of diabetes management drugs in preventing secondary complications like eye diseases. Further studies are being encouraged to validate these results in clinical settings.

?? Discover the potential of Empagliflozin in eye care

3. Nona Biosciences and Kodiak Sciences Collaborate on Novel Antibodies

Nona Biosciences and Kodiak Sciences have joined forces to develop cutting-edge antibodies targeting ophthalmic diseases.

The collaboration leverages Nona’s expertise in antibody engineering and Kodiak’s proprietary drug delivery platform to create innovative treatments for diseases such as diabetic macular edema and retinal vein occlusion.

This partnership highlights the growing role of biologics in ophthalmology, paving the way for long-lasting therapies that could dramatically improve patient outcomes.

?? Explore the science behind this collaboration

4. Fluoxetine Enhances Visual Acuity in Adults with Amblyopia

Fluoxetine, commonly known as an antidepressant, has shown promising results in improving visual acuity in adults with amblyopia (lazy eye).

Recent research demonstrates that Fluoxetine can reactivate neuroplasticity in the adult brain, providing significant visual improvements when paired with vision therapy.

This discovery challenges the traditional belief that amblyopia treatment is limited to childhood, offering new hope for adults seeking to enhance their vision.

?? Find out how Fluoxetine is breaking new ground in amblyopia treatment

Stay Updated: For more insights on the latest developments in ophthalmology, visit our website and follow us for regular updates.

Thank you for staying connected with OBN!

Enjoy our LinkedIn updates? You can also stay updated with the latest news via email.

? Click here to subscribe and never miss a story!